Singapūras - anglų - HSA (Health Sciences Authority)

sanofi-aventis singapore pte. ltd. - aflibercept - infusion, solution concentrate - 25.0 mg/ml - aflibercept 25.0 mg/ml

Singapūras - anglų - HSA (Health Sciences Authority)

sanofi-aventis singapore pte. ltd. - docetaxel trihydrate 21.34mg/ml eqv docetaxel - infusion, solution concentrate - 20mg/ml - docetaxel trihydrate 21.34mg/ml eqv docetaxel 20mg/ml

Singapūras - anglų - HSA (Health Sciences Authority)

sanofi-aventis singapore pte. ltd. - docetaxel trihydrate 85.36mg/4ml eqv docetaxel - infusion, solution concentrate - 80mg/4ml - docetaxel trihydrate 85.36mg/4ml eqv docetaxel 80mg/4ml

Singapūras - anglų - HSA (Health Sciences Authority)

sanofi-aventis singapore pte. ltd. - insulin glargine - injection, solution - 100units/ml(10.9134mg/3ml) - insulin glargine 100units/ml(10.9134mg/3ml)

Airija - anglų - HPRA (Health Products Regulatory Authority)

sanofi-aventis ireland limited t/a sanofi - aluminium oxide hydrated, magnesium hydroxide - tablets chewable - 400/400 milligram - combinations - for the relief of the symptoms of dyspepsia.

Naujoji Zelandija - anglų - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - lixisenatide 0.05 mg/ml; lixisenatide 0.1 mg/ml - solution for injection - 0.05mg/ml + 0.1mg/ml - active: lixisenatide 0.05 mg/ml excipient: glycerol hydrochloric acid metacresol methionine sodium acetate sodium hydroxide water for injection active: lixisenatide 0.1 mg/ml excipient: glycerol hydrochloric acid metacresol methionine sodium acetate sodium hydroxide water for injection - lyxumia is indicated for the treatment of adults with type 2 diabetes mellitus to achieve glycaemic control in combination with metformin, metformin and sulphonylurea, basal insulin and metformin, basal insulin and sulphonylurea when these, together with diet and exercise, do not provide adequate glycaemic control (see sections clinical trials and precautions) (risk of hypoglycemia) for available data on the different combinations.

Naujoji Zelandija - anglų - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - lixisenatide 0.05 mg/ml - solution for injection - 0.05 mg/ml - active: lixisenatide 0.05 mg/ml excipient: glycerol hydrochloric acid metacresol methionine sodium acetate sodium hydroxide water for injection - lyxumia is indicated for the treatment of adults with type 2 diabetes mellitus to achieve glycaemic control in combination with metformin, metformin and sulphonylurea, basal insulin and metformin, basal insulin and sulphonylurea when these, together with diet and exercise, do not provide adequate glycaemic control (see sections clinical trials and precautions) (risk of hypoglycemia) for available data on the different combinations.

Naujoji Zelandija - anglų - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - lixisenatide 0.1 mg/ml - solution for injection - 0.1 mg/ml - active: lixisenatide 0.1 mg/ml excipient: glycerol hydrochloric acid metacresol methionine sodium acetate sodium hydroxide water for injection - lyxumia is indicated for the treatment of adults with type 2 diabetes mellitus to achieve glycaemic control in combination with metformin, metformin and sulphonylurea, basal insulin and metformin, basal insulin and sulphonylurea when these, together with diet and exercise, do not provide adequate glycaemic control (see sections clinical trials and precautions) (risk of hypoglycemia) for available data on the different combinations.

Malaizija - anglų - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

sanofi-aventis (malaysia) sdn. bhd. - insulin glargine -

Malaizija - anglų - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

sanofi-aventis (malaysia) sdn. bhd. - insulin glulisine -